Percutaneous Cardiovascular Procedures DRG 251 Reimbursement

DRG 251 encompasses percutaneous cardiovascular procedures without intraluminal device placement and without a Major Complication or Comorbidity; it applies to catheter-based diagnostic or therapeutic interventions that do not include device implantation. This classification matters for inpatient reimbursement because it defines the prospective payment category used by Centers for Medicare & Medicaid Services for these lower-resource admissions and depends on precise coding of procedures and comorbidities.

DRG 251 Overview

DRG 251 covers hospital admissions for percutaneous cardiovascular procedures performed without placement of an intraluminal device and without a Major Complication or Comorbidity. Typical cases include diagnostic or therapeutic catheter-based interventions that do not involve stent or graft implantation and that do not have major complications affecting resource use. This Diagnosis-Related Group matters for Medicare payment because it groups relatively lower-resource percutaneous procedures into a single prospective payment category, influencing reimbursement and billing classification for inpatient stays. Accurate coding of procedures and any present complications or comorbidities determines whether an admission is classified in this Diagnosis-Related Group or in a higher-paying category.

Acute procedural optimization studies evaluating percutaneous coronary interventions performed without intraluminal devices, focusing on procedural techniques, pharmacologic adjuncts (e.g., antithrombotic regimens during the procedure), and immediate complication rates; these trials enroll patients presenting with acute coronary syndromes or symptomatic ischemia who are treated with balloon angioplasty or similar device-free percutaneous approaches. They investigate endpoints such as peri-procedural myocardial injury, access-site complications, and need for bailout stenting, which is directly relevant to providers aiming to minimize in-hospital adverse events and to payers concerned with short-term resource utilization and length of stay.
Comparative effectiveness and strategy trials comparing device-free percutaneous approaches to alternative management pathways (medical therapy optimization, staged invasive strategies, or primary stenting when indicated) in stable or unstable patients who are appropriate candidates for non-device interventions; these studies typically enroll a broader, often older population with comorbidities that influence procedural risk. They address questions about which patients derive sufficient benefit from a less-device-intensive approach versus those who should receive more invasive/device-based care, informing clinical pathways, discharge planning, and cost-effectiveness decisions that affect reimbursement and case-mix management.
Post-discharge outcomes and health services research following patients who underwent percutaneous cardiovascular procedures without intraluminal devices, tracking medium- to long-term outcomes such as recurrent ischemia, readmission rates, symptom burden, adherence to secondary prevention, and functional status; these cohort or pragmatic trials often include frail elders and medically complex patients commonly captured by this DRG. Results are important for providers and payers because they identify drivers of readmission and downstream resource use, guide transitions-of-care interventions, and support value-based reimbursement models by linking index procedural approaches to longer-term clinical and economic outcomes.

Acute procedural optimization studies evaluating percutaneous coronary interventions performed without intraluminal devices, focusing on procedural techniques, pharmacologic adjuncts (e.g., antithrombotic regimens during the procedure), and immediate complication rates; these trials enroll patients presenting with acute coronary syndromes or symptomatic ischemia who are treated with balloon angioplasty or similar device-free percutaneous approaches. They investigate endpoints such as peri-procedural myocardial injury, access-site complications, and need for bailout stenting, which is directly relevant to providers aiming to minimize in-hospital adverse events and to payers concerned with short-term resource utilization and length of stay.
Comparative effectiveness and strategy trials comparing device-free percutaneous approaches to alternative management pathways (medical therapy optimization, staged invasive strategies, or primary stenting when indicated) in stable or unstable patients who are appropriate candidates for non-device interventions; these studies typically enroll a broader, often older population with comorbidities that influence procedural risk. They address questions about which patients derive sufficient benefit from a less-device-intensive approach versus those who should receive more invasive/device-based care, informing clinical pathways, discharge planning, and cost-effectiveness decisions that affect reimbursement and case-mix management.
Post-discharge outcomes and health services research following patients who underwent percutaneous cardiovascular procedures without intraluminal devices, tracking medium- to long-term outcomes such as recurrent ischemia, readmission rates, symptom burden, adherence to secondary prevention, and functional status; these cohort or pragmatic trials often include frail elders and medically complex patients commonly captured by this DRG. Results are important for providers and payers because they identify drivers of readmission and downstream resource use, guide transitions-of-care interventions, and support value-based reimbursement models by linking index procedural approaches to longer-term clinical and economic outcomes.

OpenPayer

Summary & Overview

Percutaneous Cardiovascular Procedures without Intraluminal Device without MCC: Inpatient Reimbursement Overview

DRG 251 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes